Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US7309692B1 · kind B1 · utility
10Cited by
45References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 8, 1996 |
| Grant date | Dec 18, 2007 |
| Priority date | — |
| Expiry date | Jul 8, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/021
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crk1 nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.